Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2001, p. 2115-2118, Vol. 45, No. 7
Division of Clinical Pharmacology, Clinical
Research Initiative, Albany Medical College, Albany, New
York,1 Utah State University, Logan,
Utah,2 and The R. W. Johnson
Pharmaceutical Research Institute, Raritan, New
Jersey3
Received 21 November 2000/Returned for modification 1 April
2001/Accepted 24 April 2001
We examined RWJ-270201 in a lethal model of influenza in BALB/c
mice. The aim was to delineate the pharmacodynamically linked variable
for the drug. Challenge was performed with influenza virus
A/Shongdong/09/93 (H3N2). Treatment was administered by gavage. Five
doses (1 to 10 mg/kg of body weight) and three schedules (every 24, 12, and 8 h) were evaluated with 10 mice per group. There were 39 placebo-treated mice. Drug exposure was evaluated for infected mice.
Exposures were calculated after population modeling of all the plasma
concentration-time data simulataneously using the NPEM3 program.
Evaluation of dose and schedule with Kaplan-Meier analysis and Cox
proportional hazards modeling demonstrated that schedule offered no
explanatory power relative to dose alone. Evaluation of peak
concentration, trough concentration, and area under the
concentration-time curve (AUC) by the same methods revealed that AUC
was the dynamically linked variable. Again, schedule offered no further
explanatory power when included in the model with AUC. This indicates
that AUC is the linked variable and that the anti-influenza effect of
RWJ-270201 is independent of schedule. We conclude that once-daily
dosing of RWJ-270201 should be evaluated in clinical trials of
influenza therapy.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2115-2118.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Pharmacodynamic Evaluation of RWJ-270201, a Novel
Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts
Efficacy for Once-Daily Dosing
*
Corresponding author. Mailing address: Division of
Clinical Pharmacology, Clinical Research Institute, Albany Medical
College, Albany, NY 12208. Phone: (518) 262-6330. Fax: (518) 262-6333. E-mail: GLDRUSANO{at}AOL.COM
This article has been cited by other articles:
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»